New Product Launches & Increasing Sales Of Existing Products To Drive the market Says Kuick Research
DELHI, India, Oct. 23, 2020 (GLOBE NEWSWIRE) — “Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026” Report Highlights:
Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
Marketed Cancer Antibody Drug Conjugate: 9 Drugs
Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
Majority of Drug Trials Are For Second Line Therapy Or Greater
USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs
Download Report: https://www.kuickresearch.com/report-global-cancer-oncology-antibodies-antibody-conjugate-monoclonal-antibodies-market-size-sales-clinical-trials-growth-adcetris-sales-brentuximab
Download “Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026” Report:
Worldwide cancer is among the leading cause of death. The unprecedented level of cancer cases at a global level is increasing due to the increase in life expectancy. In this overall scenario, researchers across the world have made significant development in the medical sector and have come up with antibody drug market as a mature therapeutic area for millions of patients. Despite of all the efforts that were put in improving old and traditional therapies, researchers were not able to provide and make a remarkable change in the cancer therapeutics market but the arrival of antibody drug market for the cancer patients have helped in achieving unexpected clinical results.
The better understanding of pathophysiology of cancer have led to the discovery of novel targets present on the surface of cancer cells and eventually antibody development against the target. The discovery of several novel molecular targets on the cancer cells have refreshed the overall expectations of providing better standard healthcare for millions of cancer patients across the world. Since the development of the market that focuses on antibody development, several noteworthy advances have been made, which have eventually marked the therapy as one of the most significant markets ever made in the cancer therapeutics sector.
The further classification of the market in monoclonal antibody market and bispecific antibody market have led to the emergence of the whole market as a therapy that focuses on improving the drug selectivity and reducing the overall adverse effects, which however are some of the mainstream challenges found in the cancer market. The current panorama of the market with respect to the research and development is focused on bringing major advancement to the overall clinical platform development. In addition, the drivers coupled with the market are also believed to be providing all the regulatory updates required for the smooth functioning of the market with respect to abolishing all the challenges that were perceived as difficult when resolved through other available cancer therapies.
The global pharmaceutical sector is currently poised towards antibody market for the overall growth and expansion of both the markets i.e. antibody drug market and cancer therapeutics market. In the next few years in line, the market is estimated to be growing and providing several trends for the patients,
In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss Eli Lilly‘s (NYSE:LLY) monoclonal antibodies that target the novel coronavirus, which causes COVID-19. The company has a pair of antibodies, LY-CoV555 and LY-CoV016 that it’s testing individually and in combination with each other. After the segment was recorded, a phase 3 clinical trial testing LY-CoV555 was paused by the National Institutes of Health, which is running the study.
Corinne Cardina: Let’s talk about Eli Lilly. This company is the oldest of them all. It is 145 years old. It has a $145 billion market cap. It’s based in Indianapolis. Eli Lilly has a portfolio of medicines including treatments in bone, muscle, joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain. That’s a mouthful. They do a lot. They’ve been around for a long time.
In the second quarter of fiscal 2020, their revenue was $5.5 billion, down 2% from the same quarter the prior year. This stock also pays a dividend yielding about 2%. Eli Lilly has a neutralizing monoclonal antibody. They are calling it LY-CoV555. They call this a potent neutralizing immunoglobulin G, which is a type of monoclonal antibody, and it is directed at the spike protein of coronavirus that we just talked about. This was designed to block viral attachment and entry into human cells which would neutralize the virus, potentially prevent, and treat COVID-19.
On Sep. 16, they released proof of concept data from an interim analysis of the phase 2 clinical trial. This showed a reduced rate of hospitalization for patients who were treated with this treatment. Eli Lilly has completed enrollment and the primary safety assessments of the treatment in a phase 1 study of hospitalized patients with COVID-19 and they’re doing an ongoing long-term follow-up. A phase 2 study in people recently diagnosed with COVID-19 is going on on an outpatient basis, so the non-hospitalized patients.
Lilly recently initiated a phase 3 study for the prevention of COVID-19 specifically in residents and staff at long-term care facilities. There’s a big need there, as we know. Then lastly, the treatment is being tested in the National Institutes of Health studies of outpatient and hospitalized patients. On Wednesday, Eli Lilly announced that they had promising data for the combination of this treatment with another of their neutralizing antibody which is LY-CoV016. The company also said that it has asked the FDA for an emergency-use authorization for the initial one, 555. It plans to submit a request for an emergency-use authorization for the combination treatment next month after it gets some more safety data and it has to produce a sufficient supply. This is the second antibody that we’ve talked about. GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR) are partnered on one as well. Brian, could you explain what is a neutralizing antibody and how do these treatments differ?
Brian Orelli: Yes. A neutralizing antibody means that the antibody binds to the virus
Covid researchers are racing the clock. They’ve made enormous progress on therapies and vaccines, but they aren’t far enough along to arrest the current surge of Covid infections as winter approaches. One of the biggest challenges is making sure the new treatments reach the patients who need them most.
The most immediate opportunity comes from antibody drugs that can be used both as treatment and prophylaxis. President Trump and former New Jersey Gov. Chris Christie both recovered after they received antibody combinations when their symptoms were worsening. These medications are likely to be most effective when used before or soon after symptoms begin.
Live Q&A Event
WSJ Opinion | The 2020 Election: The Final Days, or Will It Be Weeks?
Join WSJ Opinion’s Paul Gigot, Daniel Henninger, Kyle Peterson, and Kimberley Strassel for a live discussion and Q&A on the race’s final stretch. October 21, 2020 at 8 p.m. EDT
The Food and Drug Administration is reviewing evidence for the emergency authorization of these drugs, aiming to get them to Covid patients before they need to be hospitalized. We recently wrote on these pages about some important steps to ensure an adequate supply. Available medicine will need to be used wisely on the patients who need it most.
There are also practical challenges of administering these medicines intravenously and under medical supervision. Sending Covid patients to infusion clinics is a bad option, since those facilities are full of cancer patients and others with suppressed immune systems who may be at serious risk if infected.
The federal government is working on a system to control distribution, essentially sending limited supplies to states in proportion to their expected eligible patients. Governors would allocate the drugs to hospitals, as happened with the antiviral drug remdesivir.
This will require collaboration from states and hospitals in setting up special administration sites. Such sites might include emergency departments. But when Covid strikes a metropolitan area, stressed emergency wards may not have the space. Moreover, ideally the antibody drug would be given to patients who aren’t yet very sick. Healthy patients are often reluctant to take infused drugs, which feel riskier than swallowing pills. Having to spend three hours at a hospital will make that perception worse.
A more flexible approach would include modular sites or conversions of other hospital spaces. Health-care providers have also substantially expanded home infusion capabilities during the pandemic. It might be possible to treat some Covid patients at home, staffed by medical professionals trained to handle the small risk of allergic reactions. The FDA would need to authorize the drugs for delivery in home settings. The risk of managing reactions to the drug must be weighed against the risks that patients will avoid the hospital and forgo the therapy altogether.
A related issue is payment. Even if the antibody drug is free for patients, providers need reimbursement for the substantial costs of administering the
UC San Francisco released a preliminary analysis Thursday of data from a coronavirus testing effort in Oakland’s Fruitvale neighborhood and it confirmed what other similar studies have found: The novel coronavirus disproportionately affects the Latino community.
UCSF, in conjunction with local community groups, offered free, voluntary COVID-19 testing Sept. 26 and 27 in Fruitvale, a corner of Alameda County that has had the highest rates of COVID. Fruitvale is 50% Latino and home to one of the largest Mayan-speaking populations outside of Mexico, according to UCSF. Many residents live in multigenerational households.Read More
The Food and Drug Administration (FDA) has approved the first treatment for Zaire ebolavirus (Ebola virus). The antibody medicine, called Inmazeb, is a cocktail of anti-viral antibodies made by Regeneron Pharmaceuticals to tackle the deadly disease, which continues to ravage the Democratic Republic of Congo (DRC).
The novel treatment helps stave off the Zaire ebolavirus infection in both adult and young patients, and has been approved for widespread use after a large 2019 trial deemed it safe and effective at reducing mortality in infected patients. The medication, called REGN-EB3 (commercially Inmazeb), is most effective when administered early on during Ebola infection.
It will now be used alongside Merck’s Ervebo, the first FDA-approved vaccine for Ebola, as a two-pronged defense against the outbreaks seen across Africa.
“We are incredibly proud that the FDA has approved Inmazeb, which is also known as REGN-EB3. This is the first time the FDA has approved a treatment specifically for Ebola, which has caused a number of deadly outbreaks,” said George D. Yancopoulos, president and chief scientific officer of Regeneron, in a statement.
On June 1, 2020, the DRC announced its 11th outbreak of Ebola virus, which is still ongoing. As of September 2, the outbreak had taken the lives of 47 people. The 10th outbreak was the second largest on record and took the lives of 2,299 people within the DRC.
Inmazeb contains antibodies that bind directly to the Zaire ebolavirus and blocks the molecules that allow the virus particles to attach to the human cells. These molecules, called glycoproteins, bind to human cell receptors and provide a pathway for the virus to enter the cell, where it replicates and wages war on the immune system. Instead, the cocktail of antibodies contained in Inmazeb attach to the virus glycoprotein, blocking the binding site (epitope). By blocking this method of entry, the antibodies can prevent the virus from spreading and doing damage to host cells.
The medicine does have notable side effects, including fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting. While these symptoms were related to Inmazeb, they are also symptoms of the Ebola virus and could have been directly related to the infection instead of the medicine.
Now, Regeneron hopes to provide the life-saving medication for free to people living under the current Ebola outbreak in the DRC, as part of the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol for compassionate use. The USA has also ordered Inmazeb in preparation for any potential public health emergencies in the future.
However, Inmazeb is not the only project Regeneron has been working on. You may recognize the name from a different antibody medicine (REGN-COV2) taken by US President Donald Trump during his battle with Covid-19. The company is still actively working toward a safe and effective Covid-19 treatment, and whilst the REGN-COV2 looks promising, it is still in the experimental phase.